Table 1 Baseline characteristics of the study groups
Metformin | Placebo | |
|---|---|---|
No. of subjects | 10 | 9 |
Age (yrs) | 26.10 ± 4.25 | 27.89 ± 4.83 |
Weight (kg) | 78.97 ± 21,86 | 95.26 ± 21.64 |
BMI (kg/m2) | 29.90 ± 7.41 | 32.15 ± 6.10 |
No. with oligomenorrhea (%) | 10 (100%) | 8 (89%) |
No. with PCO on ultrasound (%) | 8 (80%) | 7 (78%) |
Total testosterone (μg/l) | 0.58 ± 0.24 | 0.66 ± 0.36 |
SHBG (nmol/l) | 35.60 ± 24.09 | 39.02 ± 33.30 |
Free testosterone (pg/ml) | 1.77 ± 0.99 | 1.92 ± 0.91 |
Androstendione (μg/l) | 3.65 ± 1.47 | 3.61 ± 0.91 |
17-OHP (μg/l) | 1.35 ± 0.37 | 1.22 ± 0.49 |
Free androgen Index | 7.78 ± 4.96 | 7.92 ± 3.26 |
Estradiol (ng/l) | 36.56 ± 14.06 | 48.00 ± 20.77 |
DHEAS (mg/l) | 2.50 ± 0.97 | 1.84 ± 0.79 |
Fasting glucose (mg/dl) | 81.80 ± 6.03 | 86.89 ± 6.57 |
AUC glucose | 18409.70 ± 2059.30 | 17987.67 ± 2264.72 |
(mg/dl x 180 min) | ||
Fasting insulin (μIU/ml) | 11.06 ± 6.38 | 18.04 ± 10.66 |
AUC insulin | 12754.40 ± 8060.54 | 16671 ± 12663.37 |
(μUI/ml x 180 min) | ||
No. with IR* (%) | 3 (30%) | 5 (56%) |